Interest Groups

IG - Allergy Diagnosis & Systems Medicine

  • Business Meeting - 2 August 2018

    Please find the minutes from the Allergy Diagnosis and Systems Medicine business meeting here
    Last updated: 08 October 2018
  • Business Meeting - 27 May 2018

    Please find the minutes from the Allergy Diagnosis and Systems Medicine business meeting here.
    Last updated: 08 October 2018
  • Position Paper - Muraro et al. 2018

    The accurate assessment and communication of the severity of acute allergic reactions are important to patients, clinicians, researchers, the food industry, and public health and regulatory authorities. Severity has different meanings to different stakeholders with patients and clinicians rating the significance of particular symptoms very differently. Many severity scoring systems have been generated, most focusing on the severity of reactions following exposure to a limited group of allergens. They are heterogeneous in format, none has used an accepted developmental approach, and none has been validated. Their wide range of outcome formats has led to difficulties with interpretation and application. Therefore, there is a persisting need for an appropriately developed and validated severity scoring system for allergic reactions that work across the range of allergenic triggers and address the needs of different stakeholder groups. We propose a novel approach to develop and then validate a harmonized scoring system for acute allergic reactions, based on a data‐driven method that is informed by clinical and patient experience and other stakeholders’ perspectives. We envisage two formats: (i) a numerical score giving a continuum from mild to severe reactions that are clinically meaningful and are useful for allergy healthcare professionals and researchers, and (ii) a three‐grade‐based ordinal format that is simple enough to be used and understood by other professionals and patients. Testing of reliability and validity of the new approach in a range of settings and populations will allow eventual implementation of a standardized scoring system in clinical studies and routine practice.

    Read the full article here.
    Last updated: 29 August 2018
  • ISMA 2017 Report

    Report from ISMA 2017

    The seventh International Symposium on Molecular Allergology (ISMA), chaired by Markus Ollert, was held on 9–11 November 2017 in Luxembourg. The Luxembourg Society for Allergology and Immunology (LSAI) has only been a member society of EAACI since 2013 and this was the first EAACI meeting held in Luxembourg. ISMA 2017 was a truly international meeting with 300 registered participants and faculty members from 42 countries.

    The scientific programme was compiled in a joint effort by members of the EAACI Interest Group on Allergy Diagnosis and Systems Medicine and the EAACI Immunology Section together with Lars Poulsen (Denmark, past EAACI Vice President Congresses). This year, ISMA offered a novel format – plenary sessions summarising state-of-the-art knowledge delivered by leading scientists in the field alternating with parallel symposia in which selected topics were presented in depth. Alongside the themes for which the Symposium has built its innovative reputation – the molecular allergen approach which enabled modern component-resolved IgE diagnosis and novel forms of allergen immunotherapy – the new second ISMA track covered emerging fields of molecular and systems biomedicine relevant to the field of allergy and clinical immunology; a delegate survey will evaluate whether the new format was appreciated. The more classical ISMA topics included presentations on the allergome, an analysis of molecular allergen structures and challenges in molecular diagnosis and therapy of allergic diseases. The meeting was of an excellent scientific quality throughout. Cutting-edge results were presented both in lectures and on posters and there was a very active and inspiring scientific exchange in all sessions.

    A total of 78 scientific abstracts were presented either as oral presentations (8) or as posters (70). Poster sessions were well attended and allowed for fruitful scientific discussions between presenters and participants.

    ISMA 2017 with its new structure and a broader definition of molecular topics relevant for precision medicine in allergy has once again provided an excellent platform to exchange the latest scientific knowledge to ensure what is ultimately needed – a future impact on patients.
    Last updated: 20 February 2018
  • Current Activities in IGAD

    EuroBAT 2014 was be held in Munich together with the last meeting of the COST funded EMBRN meeting, arranged by Bernadette Eberlein with assistance from Edward Knol, Christabolina Mayorga and Hans Jürgen Hoffmann. The next EuroBAT will be held in 2016. Previous EuroBAT meetings have been held annually since 2007.

    Lois Delgado and Paolo Matricardi are chairs for the ISMA 2015 from 19-21 November 2015 at the Fundação Champalimaud, in Lisbon, Portugal. The most recent ISMA was held in Vienna, 2013

    e-PAD: EAACI Practical Allergy Diagnosis Summer School in Moscow 29.08-01.09, 2015; applied for by Hans Jürgen Hoffmann, Musa Khaitov and Christian Lupinek.


    Ongoing Task Forces of the IGAD:

    Clinical Impact of BAT, initiated 2013 – HJ Hoffmann
    Availability of Diagnostic Allergens in Europe, applied 2014 – A Kalpaklioglu, V Cardona
    Component Resolved IgE detection as an improved diagnostic tool, initiated 2013 – P Matricardi, M Ollert, R Valenta


    Task Forces originating in other IGs or Sections:

    Allergy Nomenclature Task Force Meeting, 2014 – C Akdis, C Lupinek
    Pædiatric Allergy Diagnosis, 2012 – M Roberts, M Ollert
    Vaccinations and Allergy, 2013 – Lennard Nilsson, Christoph Grüber, V Cardona


    Untitled-1
    Last updated: 21 January 2016
  • EuroBAT 2013 Report

    EuroBAT 7

    66 researchers and clinicians from 19 countries* participated in the 7th EuroBAT Meeting - an EAACI Focused Meeting - in Malaga, Spain on 18th of September 2013.

    The 7h EUROBAT meeting started with a presentation of the EAACI Task Force “Clinical Impact of BAT” followed by a session on pressing issues in basophil activation. We discussed evaluation of patients allergic to food, hymenoptera and inhalant allergens with the basophil activation test, and discussed clinical and technical issues. The European Network of Drug Allergy (ENDA) joined us for the afternoon session during which the emphasis was on drug allergy diagnosis. The meeting concluded with a dinner in the port of Malaga.

    Thanks to our sponsors; BÜHLMANN, EXBIO Praha, a.s. and Thermo Fisher Scientific for their continued support.
    We hope all attendants had an enjoyable and productive stay in Malaga.
    We will arrange the next EuroBAT meeting with EMBRN in Munich, 11-12. 12. 2014.

    EuroBAT Organising Committee

    Hans Jürgen Hoffmann, Bernadette Eberlein, Cristobalina Mayorga, Edward Knol
    * Brazil, Czech Republic, Denmark, France, Germany, Greece, Italy, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom & United States


    EuroBAT2013
    Last updated: 21 January 2016
  • IGAD Business Meeting 2008 in Barcelona

    Ola! welcome to our meeting!

    Last updated: 03 July 2009
  • Allergy Diagnosis Business Meeting in Vienna 2006

    This resource is for EAACI members only. To log-in use your EAACI username & password. If you are not a member of the EAACI, click here to join us.
    Last updated: 20 July 2009
  • Training Course in Food Allergy Cork, Ireland 13-15th September 2007

    The 2nd EAACI/GA2LEN training course in food allergy

    Last updated: 15 July 2009
  • Allergy Diagnosis IG in Vienna 2006

    Invitation for the Business Meeting of Allergy Diagnosis IG in XXV EAACI Congress in Vienna 2006.

    Last updated: 15 July 2009
  • TF Clinical Impact of BAT

    The aim of the TF Clinical Impact of BAT is to write a state of the art article with evidence for, as well as a vision of, the significance of the Basophil Activation Test in the diagnosis of allergy. The TF has 21 members from 12 countries. We have met in Zürich and Milan, held a number of telephone conferences, and plan to meet once more in Málaga, where we will start disseminating our findings. We expect to complete our mission in 2013.

    We have identified applications of BAT in diagnosis and monitoring of allergic disease, discuss the way in which the test is used, and how this can be optimized. We will disseminate our findings at EuroBAT and EAACI international meetings as well as through a peer reviewed state of the art article.

    Contact: Hans Jürgen Hoffmann, hans.jurgen.hoffmann@ki.au.dk
    Last updated: 24 September 2014
  • 4th EuroBAT: Report on the Munich meeting

    The 4th EuroBAT meeting (30.10 – 01.11.2010) covered both the well-known application of identifying response to “difficult” allergens by ex vivo basophil activation as well as more advanced, novel applications in which determination of sensitivity played a role. Sixty participants from 14 Countries (as far way as Brazil and Australia) attended, and all 23 abstracts accepted were presented as 10-minute talks.

    The meeting was organised by Ed Knol, Claude Lambert, Hans Jürgen Hoffmann and Bernadette Eberlein as local organiser, who did most of the actual work with two colleagues from her clinic. Overall, the meeting turned out to be very informative and stimulating for both experts in the field as well as many newcomers in the field. The organizing committee is very pleased that the EAACI executive has endorsed EuroBAT meetings, and we look forward to better integration of this promising test in allergy diagnosis and monitoring. Hans Jürgen Hoffmann has taken over from Didier Ebo as spokesperson for EuroBAT in the EAACI.

    The next meeting of the EuroBAT is planned with the ENDA group in Verona in late September 2011. Details will be available on basophil.org and here.

    Link to ISMA
    Last updated: 21 January 2016
  • 4th EuroBAT: Scientific & Social Report from Munich

    The programme was structured with open presentation sessions reflecting the organisation of EuroBAT. The invited lecture by Anna Nopp, Ph.D. was on basophil sensitivity and its use in diagnosis and monitoring of therapy, and a rising interest in basophil sensitivity was evident in a number of talks. One session was devoted to each topic addressed by the working groups 1. Technical Issues, 2. Drug Allergy, 3. Hymenoptera and Pollen Allergy and Immunotherapy, and 4. Food Allergy. Paralell workshops were arranged for the working groups, in which participants shared their experience, problems and solutions by facilitated scientific exchange between participants and planned new actions. The working groups conclusions were summarised in a plenum session. The social highlight of the meeting was dinner in the rotating restaurant atop the Olympia Centres’ TV tower with a splendid view of Munich by night.

    Link to ISMA

    Last updated: 14 December 2014
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel